Vaxcell Bio Therapeutics Co Stock Cash Flow From Operations
| 323990 Stock | KRW 9,380 60.00 0.64% |
Vaxcell Bio Therapeutics Co fundamentals help investors to digest information that contributes to Vaxcell-Bio Therapeutics' financial success or failures. It also enables traders to predict the movement of Vaxcell-Bio Stock. The fundamental analysis module provides a way to measure Vaxcell-Bio Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaxcell-Bio Therapeutics stock.
Vaxcell-Bio |
Vaxcell Bio Therapeutics Co Company Cash Flow From Operations Analysis
Vaxcell-Bio Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Vaxcell-Bio Therapeutics Cash Flow From Operations | (4.66 B) |
Most of Vaxcell-Bio Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaxcell Bio Therapeutics Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Vaxcell Bio Therapeutics Co has (4.66 Billion) in Cash Flow From Operations. This is much lower than that of the sector and significantly lower than that of the Cash Flow From Operations industry. The cash flow from operations for all Republic of Korea stocks is notably higher than that of the company.
Vaxcell-Bio Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaxcell-Bio Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaxcell-Bio Therapeutics could also be used in its relative valuation, which is a method of valuing Vaxcell-Bio Therapeutics by comparing valuation metrics of similar companies.Vaxcell Bio is currently under evaluation in cash flow from operations category among its peers.
Vaxcell-Bio Fundamentals
| Return On Equity | -21.18 | |||
| Current Valuation | 1.06 T | |||
| Shares Owned By Insiders | 13.55 % | |||
| Shares Owned By Institutions | 3.92 % | |||
| Gross Profit | (5.39 M) | |||
| EBITDA | (4.06 B) | |||
| Net Income | (4.76 B) | |||
| Cash And Equivalents | 27.31 B | |||
| Total Debt | 37.39 M | |||
| Cash Flow From Operations | (4.66 B) | |||
| Market Capitalization | 554.12 B | |||
| Total Asset | 31.28 B | |||
| Net Asset | 31.28 B |
About Vaxcell-Bio Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaxcell Bio Therapeutics Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxcell-Bio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxcell Bio Therapeutics Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Vaxcell-Bio Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vaxcell-Bio Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxcell-Bio Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Vaxcell-Bio Stock
The ability to find closely correlated positions to Vaxcell-Bio Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vaxcell-Bio Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vaxcell-Bio Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vaxcell Bio Therapeutics Co to buy it.
The correlation of Vaxcell-Bio Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vaxcell-Bio Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vaxcell-Bio Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vaxcell-Bio Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Vaxcell-Bio Stock
Vaxcell-Bio Therapeutics financial ratios help investors to determine whether Vaxcell-Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vaxcell-Bio with respect to the benefits of owning Vaxcell-Bio Therapeutics security.